Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 7/20 | 0.36 |
| ▸ | POLQ | O75417 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17047832 | 0.95 | NLRP3 (0.43) | LRRK2NLRP3SSTR4CDK9POLQ | |
| SCHEMBL12209161 | 0.85 | LRRK2 (0.41) | LRRK2NLRP3CYP11B1CYP11B2SSTR4 | |
| SCHEMBL12209156 | 0.81 | LRRK2 (0.43) | LRRK2NLRP3SSTR4CDK9CCNT1 | |
| SCHEMBL17054291 | 0.78 | CDK9 (0.42) | LRRK2NLRP3SSTR4CDK9 | |
| SCHEMBL3111541 | 0.73 | CCNT1 (0.37) | SSTR4CDK9CCNT1 | |
| SCHEMBL5124999 | 0.72 | CYP11B1 (0.39) | NLRP3CYP11B1CYP11B2SSTR4CDK9 | |
| SCHEMBL22050209 | 0.70 | EPHX2 (0.51) | — | |
| SCHEMBL1812696 | 0.69 | HTR2A (0.44) | NLRP3CYP11B1CYP11B2SSTR4CDK9 | |
| SCHEMBL16814051 | 0.69 | NTRK1 (0.40) | NLRP3CYP11B1CYP11B2SSTR4CDK9 | |
| SCHEMBL20207558 | 0.69 | NTRK1 (0.40) | NLRP3CYP11B1CYP11B2SSTR4CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220332705-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2022-10-20 | — | — | US | disclosed |
| US-10759783-B2 | Biaryl inhibitors of Bruton'S tyrosine kinase | BIOGEN MA INC. (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3110818-B1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190218204-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2019-07-18 | — | — | US | disclosed |
| US-10253044-B2 | 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-04-09 | — | — | US | disclosed |
| EP-2844658-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | GENENTECH INC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10081619-B2 | Biaryl inhibitors of bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2018-09-25 | — | — | US | disclosed |
| EP-3080103-B9 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2018-09-19 | — | — | EP | disclosed |
| EP-3357921-A2 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | Sunesis Pharmaceuticals, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20170210761-A1 | 9H-PYRIMIDO [4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-07-27 | — | — | US | disclosed |
| EP-3110818-A1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | The Regents of The University of Michigan (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20160311802-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2016-10-27 | — | — | US | disclosed |
| EP-3080103-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | Biogen MA Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9212186-B2 | Bicyclic pyrazole LRRK2 small molecule inhibitors | GENENTECH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| WO-2015131005-A1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015089337-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN IDEC MA INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| EP-2844658-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2015-03-11 | — | — | EP | disclosed |
| US-20150051201-A1 | BICYCLIC PYRAZOLE LRRK2 SMALL MOLECULE INHIBITORS | GENENTECH, INC. (US) | 2015-02-19 | — | — | US | disclosed |
| WO-2013164323-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | ABL1, BTK, LYN | LRRK2 228/4885NLRP3 4114/4885CYP11B1 1860/4885 |
| US-10759783-B2 | Biaryl inhibitors of Bruton'S tyrosine kinase | ABL1, BTK, LYN | LRRK2 228/4885NLRP3 4114/4885CYP11B1 1860/4885 |
| US-10081619-B2 | Biaryl inhibitors of bruton's tyrosine kinase | ABL1, BTK, LYN | LRRK2 228/4885NLRP3 4114/4885CYP11B1 1860/4885 |
| US-20170210761-A1 | 9H-PYRIMIDO [4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | LRRK2 563/4885NLRP3 3511/4885CYP11B1 1473/4885 |
| US-20220332705-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | LRRK2 228/4885NLRP3 4114/4885CYP11B1 1860/4885 |
| US-20190218204-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | LRRK2 228/4885NLRP3 4114/4885CYP11B1 1860/4885 |
| US-20150051201-A1 | BICYCLIC PYRAZOLE LRRK2 SMALL MOLECULE INHIBITORS | LRRK2, PARK7, PINK1 | LRRK2 1/4885NLRP3 199/4885CYP11B1 2562/4885 |
| US-20160311802-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | LRRK2 228/4885NLRP3 4114/4885CYP11B1 1860/4885 |
| US-10253044-B2 | 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors | BRD4, BRD3, BRD1 | LRRK2 563/4885NLRP3 3511/4885CYP11B1 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.